Switch to
More onapp

How to use scorecard? Learn more

Marksans Pharma Ltd

MARKSANS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,633 cr, stock is ranked 570
High RiskStock is 3.61x as volatile as Nifty
160.832.21 (+1.39%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,633 cr, stock is ranked 570
High RiskStock is 3.61x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
24.33
PB RatioPB Ratio
4.32
Dividend YieldDiv. Yield
0.36%
Sector PESector PE
41.34
Sector PBSector PB
5.97
Sector Div YldSctr Div Yld
0.61%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.

Investor PresentationView older 

Aug 11, 2023

PDF
View Older Presentations

Financial TrendFinancial statements 

20212022202320241.381.531.912.230.240.180.270.31
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnApr 18, 2024

Marksans Pharma Limited has informed the Exchange regarding a press release dated April 18, 2024, titled "USFDA inspection at Company's manufacturing facility in Verna, Goa, India". | Download

Marksans Pharma Limited has informed the Exchange regarding a press release dated April 18, 2024, titled "USFDA inspection at Company's manufacturing facility in Verna, Goa, India". | Download

Cash Dividend 
Ex. DateJun 7, 2023

Final • Div/Share: ₹ 0.5

Cash Dividend 
Ex. DateAug 19, 2022

Final • Div/Share: ₹ 0.25

See all events